Literature DB >> 2021798

Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy.

W T Millar1.   

Abstract

The linear-quadratic (LQ) model for fractionated external beam therapy has been modified by previous authors to include the effects due to an exponentially decaying dose rate. However, the LQ model has now been extended to include a general time varying dose rate profile, and the equations can be readily evaluated if an exponential radiation damage repair process is assumed. These equations are applicable to radionuclide directed therapy, including brachytherapy. Kinetic uptake data obtained during radionuclide directed therapy may therefore be used to determine the radiobiological dosimetry of the target and non-target tissues. Also, preliminary tracer studies may be used to pre-plan the radionuclide directed therapy, provided that tracer and therapeutic amounts of the radionuclide carrier are identically processed by the tissues. It is also shown that continuous radionuclide therapy will induce less damage in late-responding tissues than 2 Gy/fraction external beam therapy if the ratio of the maximum dose rate and the sublethal damage repair half-life in the tissue is less than 1.0 Gy. Similar inequalities may be derived for beta-particle radionuclide directed therapy. For example, it can be shown that radionuclide directed therapy will induce less damage to slowly repopulating tissue than 2 Gy/fraction external beam therapy for the same total dose if the maximum percentage initial uptake in tissue is less than 0.046%/g or 0.23%/g for an injected activity of 50 mCi of 90Y or 131I, respectively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2021798     DOI: 10.1259/0007-1285-64-759-242

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  16 in total

1.  Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.

Authors:  Hanan Amro; Scott J Wilderman; Yuni K Dewaraja; Peter L Roberson
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

2.  Calculation of the biological effective dose for piecewise defined dose-rate fits.

Authors:  Robert F Hobbs; George Sgouros
Journal:  Med Phys       Date:  2009-03       Impact factor: 4.071

3.  Radiobiological considerations for radioembolization with 188Re-microspheres.

Authors:  Liane Oehme; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-19       Impact factor: 9.236

4.  Cellular Response to Exponentially Increasing and Decreasing Dose Rates: Implications for Treatment Planning in Targeted Radionuclide Therapy.

Authors:  Jay H Solanki; Thomas Tritt; Jordan B Pasternack; Julia J Kim; Calvin N Leung; Jason D Domogauer; Nicholas W Colangelo; Venkat R Narra; Roger W Howell
Journal:  Radiat Res       Date:  2017-05-25       Impact factor: 2.841

5.  The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model.

Authors:  Joseph J Grudzinski; Wolfgang Tomé; Jamey P Weichert; Robert Jeraj
Journal:  Phys Med Biol       Date:  2010-09-08       Impact factor: 3.609

Review 6.  Three-dimensional imaging-based radiobiological dosimetry.

Authors:  George Sgouros; Eric Frey; Richard Wahl; Bin He; Andrew Prideaux; Robert Hobbs
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

7.  Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.

Authors:  R F Hobbs; W Jentzen; A Bockisch; G Sgouros
Journal:  Q J Nucl Med Mol Imaging       Date:  2013-03       Impact factor: 2.346

8.  Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry.

Authors:  Sébastien Baechler; Robert F Hobbs; Andrew R Prideaux; Richard L Wahl; George Sgouros
Journal:  Med Phys       Date:  2008-03       Impact factor: 4.071

9.  A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin).

Authors:  Massimiliano Pacilio; Margherita Betti; Francesco Cicone; Carolina Del Mastro; Livia Montani; Laura Chiacchiararelli; Alessia Monaco; Enrico Santini; Francesco Scopinaro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

10.  Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.

Authors:  Andrew R Prideaux; Hong Song; Robert F Hobbs; Bin He; Eric C Frey; Paul W Ladenson; Richard L Wahl; George Sgouros
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.